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RETROSPECTIVE COHORT STUDY OF TAMOXIFEN TREATED
BREAST CANCER PATIENTS ASSOCIATED WITH RISK OF
ENDOMETRIAL CANCER
Wang C, He J, Grifﬁn B, Mahoney A, Burleigh E
Solucient, Berkerley Heights, NJ, USA
OBJECTIVES: Treatment of breast cancer with Tamoxifen has
been reported debatably associated with endometrial cancer.
This retrospective cohort study is aiming to track breast cancer
patients to ﬁnd out if Tamoxifen usage is associated with occur-
rence to endometrial cancer in a commercially insured claims
outpatient setting. METHODS: A cohort of 5037 breast cancer
patients diagnosed between July 2000 and June 2001 was estab-
lished from Solucient outpatient database with prior 6 month
deﬁned as cohort clearance time. Based on the data warehouse
the cohort had been followed up until June 2005 as observation
period. Patients were divided into three groups based on the
cumulative duration of Tamoxifen use (A, 0 years; B, 1–2 years;
C, >3–4 years). Cox proportional hazard regression model was
used to examine the relationships between endometrial cancer
and Tamoxifen usage with inﬂuencing factors age, region and
cormorbidities controlled. X2 and Hazard Ratio (HR) were cal-
culated. RESULTS: Endometrial cancer was found in 39/3831
(1.02%) breast cancer patients in group A, 6/786 (0.76%) in
group B, and 4/420 (0.95%) in group C. No signiﬁcant differ-
ence was observed among the 3 groups (X2 = 0.441, p = 0.802).
In Cox Proportional Hazard regression model, Tamoxifen was
not found to have had signiﬁcant effect (HR = 0.967, P = 0.256)
and none of the inﬂuencing factors including age, region, dia-
betes mellitus and hypertension were found to signiﬁcantly con-
tribute to occurrence of the events (P > 0.05). CONCLUSION:
The study showed no association between use of Tamoxifen of
breast cancer and endometrial cancer occurrence in four years of
retrospective cohort observation. The observation period may
not be long enough and extended period is needed to conﬁrm
the ﬁnding.
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QUALITY IN HEALTH CARE SERVICES FOR WOMEN WITH
BREAST CANCER AND ITS ECONOMIC CONSEQUENCES 
IN MEXICO
Contreras-Hernandez I1, Mould J1, Pico-Guzman J2,
Ayala-Hernandez JR1, Garduño-Espinosa J1
1Social Security Mexican Institute, Mexico City, Mexico, 2Life Sciences
Consulting, Madrid, Spain
OBJECTIVES: In Mexico, breast cancer is the second most fre-
quent cancer in oncology patients so high quality health care ser-
vices and an efﬁcient resource use is a priority. This study assesses
to identify improvement health care areas for patients with
breast cancer and estimates its economic impact in the Social
Security Mexican Institute. METHODS: A study was performed
for breast cancer patient’s health care process in the biggest
oncology hospital of Mexico City throughout 2003, to identify
patient’s clinical phases, resource use and timing for services.
With the aid of oncologist experts, treatment maps were con-
structed for each clinical phase. Hospital records were used to
calculate the number of patients treated in each phase and with
the support of structured questionnaires, efﬁcient levels of oncol-
ogy services were identiﬁed. The study estimated clinical
improvements and potential ﬁnancial savings. The estimates
were conducted from the health care payer’s perspective. All
costs were expressed in 2005 US$. RESULTS: One hundred four
women with breast cancer were recruited; 36.4% of patients
were in phases III and IV, and inefﬁciencies were observed in the
hospital central services. Extrapolating the sample results to the
overall breast cancer population in the Social Security Mexican
Institute (n = 3375); annual direct expected medical costs were
US$73.8 million. Improving early detection up to 89% of
women in phases I and II; and sending these women directly to
third level oncology services will improve process efﬁciency and
ﬁnancial savings could reach US$10.5 millions (14.2% of total
breast cancer expenditures). Also, reductions on the timing cycle
for health care services to 150 days and improvements on 
the survival length in 16% would give the Mexican Health
System similar savings. CONCLUSIONS: Improving early 
detection/quality health care services would obtain important
clinical beneﬁts for breast cancer patients and signiﬁcant savings
for Mexican health institutions.
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HOSPITAL INPATIENT UTILIZATION OF EPOETIN ALFA (EPO)
AND DARBEPOETIN ALFA (DARB) IN PATIENTS WITH
CANCER AND PRE-DIALYSIS CHRONIC KIDNEY 
DISEASE (PCKD)
Smith J1, He J1, Mahoney A1, Noone P2,Watson S3, Mody S3,
McKenzie RS3
1Solucient, LLC, Berkeley Heights, NJ, USA, 2Ortho Biotech Products,
LP, Bridgewater, NJ, USA, 3Ortho Biotech Clinical Affairs, LLC,
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OBJECTIVES: To evaluate recent dosing patterns and associated
drug costs of EPO and DARB for inpatient hospital pCKD and
cancer patients. METHODS: Discharge data from 518 geo-
graphically diverse hospitals were used to select cancer or pCKD
patients who were admitted to the hospital between January
2003 and June 2005. Patients were included if they received EPO
or DARB during the course of their inpatient stay and were
excluded if diagnosed with HIV, underwent a surgical procedure,
or received both EPO and DARB during the same admission.
The dose only ratio was calculated as the ratio of the weighted
mean EPO and DARB daily dose (units EPO: mcg DARB) with
cost based on the average daily dose and 2005 wholesale acqui-
sition cost. RESULTS: A total of 53,679 EPO and 7669 DARB
cancer patients were identiﬁed with an average daily dose of EPO
5081 Units/day and DARB 19.7mcg/day. This corresponded to
a dose only ratio of 258 :1 (Units EPO: mcg DARB) and a daily
cost of EPO $62 and DARB $86. A total of 51,660 EPO and
4522 DARB pCKD patients were identiﬁed with an average daily
dose of EPO 3253 Units/day and DARB 12.4mcg/day. This cor-
responded to a dose only ratio of 262 :1 and a daily cost of EPO
$40 and DARB $54. CONCLUSIONS: This observational study
of >117,000 inpatients demonstrated dose only ratios of approx-
imately 260 :1 in cancer and pCKD patients. Drug costs were
39% and 35% higher in the DARB group for cancer and pCKD
patients, respectively. Consistent with previous observational
studies in outpatients, these ﬁndings provide dose only ratios,
which are seen in actual hospital practice. Awareness of these
dose only ratios are of importance to health care professionals,
hospital administrators, payors, and policy makers.
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